- Trials with a EudraCT protocol (23)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
23 result(s) found for: Catabolic.
Displaying page 1 of 2.
EudraCT Number: 2005-001762-13 | Sponsor Protocol Number: sepsis 1 | Start Date*: 2005-07-13 |
Sponsor Name:Universitätskinderklinik Heidelberg | ||
Full Title: Energy metabolism of critically ill children treated with lipid emulsion and carnitine | ||
Medical condition: The primary purpose of the study is an examination of the ability of lipid emulsions and carnitin supplementation to reduce the morbidity associated with sepsis and catabolic conditions by altering... | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-003504-12 | Sponsor Protocol Number: GK_nilani_2012 | Start Date*: 2012-10-05 |
Sponsor Name:Medical Research Laboratory, Clinical institute of Medicine, Aarhus University Hospital | ||
Full Title: Glucocorticoid-induced inhibition of IGF-I activity: exploration of underlying mechanisms. | ||
Medical condition: The catabolic effects induced by long-term glucocorticoid treatment. | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-005075-40 | Sponsor Protocol Number: 2013-005075-40 | Start Date*: 2014-04-08 |
Sponsor Name:Research Programs' Unit, Diabetes & Obesity, University of Helsinki | ||
Full Title: The effect of Liraglutide treatment on postprandial chylomicron and VLDL kinetics, liver fat and de novo lipogenesis. A single-center randomized controlled study. | ||
Medical condition: Type 2 diabetes | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001716-71 | Sponsor Protocol Number: RIMON_C_01346 | Start Date*: 2006-09-12 | |||||||||||
Sponsor Name:sanofi aventis Groupe | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE BLIND, TWO ARM, PARALLEL, PLACEBO CONTROLLED STUDY OF RIMONABANT 20MG EFFECT ON HIGH DENSITY LIPOPROTEIN KINETICS IN PATIENTS WITH ABDOMINAL OBESITY AND ADDITIONAL CARDIOMETABO... | |||||||||||||
Medical condition: PATIENTS WITH ABDOMINAL OBESITY AND ADDITIONAL CARDIOMETABOLIC RISK FACTORS | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) GB (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002638-35 | Sponsor Protocol Number: 3.00 | Start Date*: 2012-07-31 |
Sponsor Name:Stockholms Läns Landsting, Karolinska Universitetssjukhuset Huddinge, Anestesikliniken | ||
Full Title: ALBUMIN KINETICS BY 123I-HSA A validation study on healthy volunteers, patients with acute inflammation, and patiens scheduled for major abdominal surgery | ||
Medical condition: A) healthy volunteers (transcapillary escape rate of albumin, plasmavolume, and turnover of albumin) B) Acute inflammation such as pancreatitis or cholecystitis C) Scheduled major abdominal surge... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-020114-29 | Sponsor Protocol Number: IGFHD1-2010 | Start Date*: 2010-07-13 | |||||||||||
Sponsor Name:Department of Nephrology | |||||||||||||
Full Title: Insulin-like growth factor in hemodialysis patients | |||||||||||||
Medical condition: This project aims to investigate whether the anabolic potentials of insulin may be used to reverse the catabolic effects of hemodialysis in non-diabetic patients with end-stage renal failure. Thus... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001176-30 | Sponsor Protocol Number: 20167169 | Start Date*: 2016-06-15 |
Sponsor Name:Clinical Research Institute, HUCH Ltd. | ||
Full Title: Effects of PCSK9 inhibition by Evolocumab on postprandial lipid metabolism in type 2 diabetes | ||
Medical condition: type 2 diabetes | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002008-41 | Sponsor Protocol Number: GR-MET-19 | Start Date*: 2019-09-05 | |||||||||||
Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI | |||||||||||||
Full Title: Effect of metyrapone on cardiovascular risk factors in patients with adrenal incidentalomas and subclinical/mild Cushing's syndrome | |||||||||||||
Medical condition: patients with adrenal incidentalomas and subclinical/mild Cushing’s syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002329-56 | Sponsor Protocol Number: FISIO | Start Date*: 2021-10-19 | |||||||||||
Sponsor Name:Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC) | |||||||||||||
Full Title: Exploratory study to evaluate the efficacy and safety of nutritionally administering 1.5 g protein/kg/day vs. 1.0 g protein/kg/day in the catabolic phase of the critically ill patient on mechanical... | |||||||||||||
Medical condition: Acquired Weakness in the Intensive Care Unit (DAUCI) of the critically ill patient. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002316-23 | Sponsor Protocol Number: CKJX839C12001B | Start Date*: 2023-01-16 | |||||||||||
Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||
Full Title: An open-label, single arm, multicenter extension study to evaluate long-term safety and tolerability of inclisiran in participants with heterozygous or homozygous familial hypercholesterolemia who... | |||||||||||||
Medical condition: Familial Hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Ongoing) NO (Trial now transitioned) DE (Ongoing) NL (Trial now transitioned) HU (Ongoing) GR (Trial now transitioned) FR (Ongoing) SI (Ongoing) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001023-21 | Sponsor Protocol Number: DRL-17822/CD/004 | Start Date*: 2011-06-30 | |||||||||||
Sponsor Name:DR. REDDY'S LABORATORIES LIMITED | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of DRL-17822 in Patients with Type II Hyperlipidemia | |||||||||||||
Medical condition: Hyperlipidemia Type II | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002848-41 | Sponsor Protocol Number: CAPL180A2207 | Start Date*: 2008-08-07 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled ascending dose study to evaluate the effect of APL180 on endothelial function in patients with familial hypercholesterolemia | |||||||||||||
Medical condition: familial hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022486-10 | Sponsor Protocol Number: MT-102-2001 | Start Date*: 2010-11-02 | |||||||||||
Sponsor Name:Myotec Therapeutics Limited | |||||||||||||
Full Title: A multicentre, randomised, double-blind, placebo-controlled, dose-finding phase II study to evaluate the efficacy of two different doses of MT-102 administered over a sixteen week period in subject... | |||||||||||||
Medical condition: Cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Ongoing) ES (Ongoing) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000582-37 | Sponsor Protocol Number: CHOL00107 | Start Date*: 2007-09-21 | |||||||||||
Sponsor Name:Genzyme Europe BV | |||||||||||||
Full Title: A Phase 4 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Study of Colesevelam as Add-on Therapy in Patients with Familial Hypercholesterolaemia | |||||||||||||
Medical condition: Familial hypercholesterolaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FR (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004003-23 | Sponsor Protocol Number: ISIS703802 | Start Date*: 2016-09-28 | |||||||||||||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | |||||||||||||||||||||||
Full Title: A Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ISIS 703802, Targeting ANGPTL3, Administered S... | |||||||||||||||||||||||
Medical condition: Heterozygous familial hypercholesterolemia and Homozygous familial hypercholesterolemia | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-000933-18 | Sponsor Protocol Number: HLSC-UCD-02 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Unicyte AG | |||||||||||||
Full Title: An Open-label, Non-controlled, Multi-center, Phase 2 Study to Assess the Efficacy and Safety of Allogeneic Human Liver Stem Cells (HLSCs) in the Treatment of Pediatric Patients with Early-onset Ure... | |||||||||||||
Medical condition: Urea cycle disorders | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000972-24 | Sponsor Protocol Number: D3561C00004 | Start Date*: 2014-08-20 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomized, Double blind, Placebo controlled, Multi center, Cross over Study of Rosuvastatin in Children and Adolescents (aged 6 to <18 years) with Homozygous Familial Hypercholesterolemia (HoFH) | |||||||||||||
Medical condition: Hypercholesterolemia - The current trial will study children with Homozygous Familial Hypercholesterolemia (HoFH) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) NL (Completed) BE (Completed) DK (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004084-31 | Sponsor Protocol Number: 1002-041 | Start Date*: 2023-01-23 | |||||||||||||||||||||
Sponsor Name:Esperion Therapeutics, Inc. | |||||||||||||||||||||||
Full Title: AN OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF BEMPEDOIC ACID IN PEDIATRIC PATIENTS (6 TO 17 YEARS OF AGE) WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | |||||||||||||||||||||||
Medical condition: HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) DE (Ongoing) NL (Ongoing) DK (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004964-32 | Sponsor Protocol Number: NK-104-4.01EU | Start Date*: 2012-03-29 | |||||||||||||||||||||||||||||||
Sponsor Name:Kowa Research Europe, Ltd. | |||||||||||||||||||||||||||||||||
Full Title: A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, 12-Week Study of Pitavastatin in High-Risk Hyperlipidaemia in Childhood P/266/2011, P267/2011, P268/2011 | |||||||||||||||||||||||||||||||||
Medical condition: high-risk hyperlipidaemia | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: NL (Completed) GR (Completed) FR (Completed) ES (Completed) NO (Completed) IT (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-004983-32 | Sponsor Protocol Number: NK-104-4.02EU | Start Date*: 2012-04-02 | |||||||||||||||||||||||||||||||
Sponsor Name:Kowa Research Europe, Ltd. | |||||||||||||||||||||||||||||||||
Full Title: A 52-Week Open-Label Extension and Safety Study of Pitavastatin in High-Risk Hyperlipidaemia in Childhood, P/266/2011, P/267/2011, P/268/2011 | |||||||||||||||||||||||||||||||||
Medical condition: hyperlipidaemia | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GR (Completed) NL (Completed) FR (Completed) ES (Completed) NO (Not Authorised) IT (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.